[CytoReason in The Times of Israel] Japanese pharmaceutical firm taps Israel’s CytoReason for AI drug development

Source Node: 1876727

CytoReason, an Israeli startup that uses artificial intelligence to build digital models of the human immune system and diseases to speed up drug development, said on Thursday that it was partnering with Japan’s Summit Pharmaceuticals International (SPI) to integrate its machine learning platform into the Japanese clinical drug discovery sector.

Read more here.

Source: https://blog.ourcrowd.com/japanese-pharmaceutical-firm-taps-israels-cytoreason-for-ai-drug-development/

Time Stamp:

More from OurCrowd Blog